JAK Inhibitor Structure for Broader JAK-STAT Pathway Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK inhibitors, such as Oclacitinib and Baricitinib, have limited efficacy and scope in treating inflammatory diseases and neoplastic diseases, as they do not effectively block the JAK-STAT pathway and have narrow indications, limiting their application.
Innovation Solution
A novel JAK inhibitor represented by a specific chemical formula, which includes various substituents and functional groups, is developed to inhibit JAK kinase more broadly, offering improved efficacy and wider application in both human and animal treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current JAK inhibitors (Oclacitinib, Baricitinib) are used, then they can treat some inflammatory diseases, but their efficacy is limited and they do not effectively block the JAK-STAT pathway
Solution Approach 1:
The patent modifies the chemical structure of JAK inhibitors by changing parameters such as substituent groups (R1-R8), ring structures, and molecular configuration to optimize the inhibition of JAK-STAT pathway while expanding therapeutic scope across multiple inflammatory and neoplastic diseases
Solution Approach 2:
The invention develops composite chemical structures combining multiple functional groups and moieties (e.g., heterocyclic rings, aromatic systems, linker groups) to create JAK inhibitors with enhanced efficacy and broader applicability compared to single-structure inhibitors
2Adaptability or versatility
If JAK inhibitors are designed with broader inhibition scope, then applicability to multiple diseases improves, but molecular complexity increases
Solution Approach 1:
The JAK inhibitor molecules are segmented into distinct functional domains including heterocyclic core structures, aromatic substituent groups, and linker moieties, allowing systematic optimization of each segment to achieve broad pathway inhibition while managing overall molecular complexity
Solution Approach 2:
The patent designs universal JAK inhibitor structures capable of blocking multiple JAK isoforms (JAK1, JAK2, JAK3, Tyk2) and the JAK-STAT pathway across diverse disease contexts, achieving multi-functionality through carefully selected core structures and substituent patterns
3Reliability
If existing JAK inhibitors are administered, then some therapeutic benefit is achieved, but toxicity remains a concern
Solution Approach 1:
The patent introduces specific substituent groups and structural modifications at localized positions within the JAK inhibitor molecule to enhance selective binding to JAK kinases while reducing off-target effects and toxicity, achieving improved therapeutic index through localized structural optimization
Data Source
AI summary
The present invention provides a compound represented by a general formula I and a pharmaceutically acceptable salt, stereisomer, ester, prodrug, metabolite, solvate, or deuterated compound thereof. The compound is a JAK inhibitor and can prevent and/or treat an inflammatory disease or cancer in humans and/or animals.